Vitamin K series: Current status and future prospects

Critical Reviews in Biotechnology

Volumn 35, Issue 2, 2015, Pages 199-208

  Berenjian, Aydin ^a   Mahanama, Raja ^a   Kavanagh, John ^a   Dehghani, Fariba ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biotechnology; Extraction; Fermentation; Menaquinone; Phylloquinone; Vitamin K

Indexed keywords

BIOTECHNOLOGY; EXTRACTION; FERMENTATION; KETONES;

BIOTECHNOLOGICAL APPROACHES; CARDIO-VASCULAR DISEASE; LIQUID STATE FERMENTATION; MARKET INFORMATION; MENAQUINONE; PHYLLOQUINONE; PRODUCTION PROCESS; VITAMIN K;

DISEASES;

MENAQUINONE; VITAMIN K GROUP;

CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG EFFECT; DRUG FORMULATION; DRUG ISOLATION; DRUG MARKETING; FERMENTATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TEMPERATURE SENSITIVITY; BIOTECHNOLOGY; DIETARY SUPPLEMENT; HUMAN;

BIOTECHNOLOGY; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FERMENTATION; HUMANS; OSTEOPOROSIS; VITAMIN K;

EID: 84932133919     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2013.832142     Document Type: Review

References (106)

1. Benedetti A, Daly S, Xaiz R, Pagani H. (2009). A process for the preparation of vitamin K2. European Patent 20070154998.
2. Bentley R, Meganathan R. (1982). Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol Rev, 46, 241-80.
3. Berenjian A, Mahanama R, Talbot A, et al. (2011). Efficient media for high menaquinone-7 production: response surface methodology approach. N Biotechnol, 28, 665-72.
4. Berenjian A, Mahanama R, Talbot A, et al. (2012). Advances in menaquinone-7 production by Bacillus subtilis natto: fed-batch glycerol addition. Am J Biochem Biotechnol, 8, 105-10.
5. Berenjian A, Chan NLC, Mahanama R, et al. (2013). Effect of Biofilm Formation by Bacillus subtilis natto on Menaquinone-7 Biosynthesis. Mol Biotechnol, 54, 371-8.
6. Beulens JW, Bots ML, Atsma F, et al. (2009). High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis, 203, 489-93.
7. Binkley SB, MacCorquodale DW, Thayer SA, Doisy EA. (1978). The isolation of vitamin K 1. Nutr Rev, 36, 302-4.
8. Blume SW, Curtis JR. (2011). Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int, 22, 1835-44.
9. Booth SL. (2009). Roles for vitamin K beyond coagulation. Annu Rev Nutr, 29, 89-110.
10. Booth SL, Dallal G, Shea MK, et al. (2008). Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab, 93, 1217-23.
11. Braam LA, Knapen MH, Geusens P, et al. (2003). Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int, 73, 21-6.
12. Branda SS, Vik S, Friedman L, Kolter R. (2005). Biofilms: the matrix revisited. Trends Microbiol, 13, 20-6.
13. Brodie AF, Ballantine J. (1960a). Oxidative phosphorylation in fractional bacterial systems. III. Specificity of vitamin K reactivation. J Bioi Chem, 235, 232-7.
14. Brodie AF, Ballantine J. (1960b). Phosphorylation in fractionated bacterial systems II. The role of vitamin K. J Biol Chem, 235, 226-31.
15. Chen KI, Erh MH, Su NW, et al. (2012). Soyfoods and soybean products: from traditional use to modern applications. Appl Microbiol Biotechnol, 96, 9-22.
16. Cheung AM, Tile L, Lee Y, et al. (2008). Vitamin K supplementation in postmenopausal women with osteopenia (ECKO Trial): a randomized controlled trial. PLoS Med, 5, 1461-72.
17. Christodoulou C, Cooper C. (2003). What is osteoporosis? Postgrad Med J, 79, 133-8.
18. Cockayne S, Adamson J, Lanham-New S, et al. (2006). Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med, 166, 1256-61.
19. Commercial Insight: Osteoporosis. (2009). Market players maximize revenue growth before the next challenging phase. Available form: http://www.researchandmarkets.com/reports/1382750/commercial-insight-osteoporosis-market-players.
20. Dahlöf B. (2010). Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol, 105, 3A-9A.
21. Dam H. (1935). The antihaemorrhagic vitamin of the chick: occurrence and chemical nature. Nature, 135, 652-3.
22. Dam H, Geiger A, Glavind J, et al. (1939). Isolierung des vitamins K in hochgereinigter form. Helv Chim Acta, 22, 310-3.
23. Dam H. (1966). Historical survey and introduction. Vitam Horm, 24, 295-306.
24. Daniells S. (2010). US Vitamin K market set for explosion? Available from: http://www.nutraingredients-usa.com/Industry/US-Vitamin-Kmarket-set-for-explosion.
25. Dehghani F, Kavanagh J, Talbot A, et al. (2013). Fermentation and in-situ extraction of Menaquinone-7. Australian Patent 2013900664.
26. Eisai. (2010). Available from: http://www.eisai.com/pdf/eir/erepo/epdf2010q4.pdf
27. Emaus N, Gjesdal CG, Almas B, et al. (2010). Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomized double-blind placebo-controlled trial. Osteoporos Int, 21, 1731-40.
28. European Safety. (2008). Scientific Opinion of the Panel on Dietetic Products Nutrition and Allergies on a request from the European Commission on the safety of 'Vitamin K2'. EFSA J, 822, 1-32. Available from: http://www.efsa.eu.int/science/nda/nda-opinions/catindex-en.html
29. Farrand S. Taber H. (1974). Changes in menaquinone concentration during growth and early sporulation in Bacillus subtilis. J Bacteriol, 117, 324-6.
30. Ferland G. (1998). The vitamin K-dependent proteins: an update. Nutr Rev, 56, 223-30.
31. Ferland G. (2012). The discovery of vitamin K and its clinical applications. Ann Nutr Metab, 61, 213-8.
32. Feskanich D, Weber P, Willett WC, et al. (1999). Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr, 69, 74-9.
33. Gast GC, de Roos NM, Sluijs I, et al. (2009). A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovas, 19, 504-10.
34. GCDM. (2010). Global Cardiovascular Drugs Market to Exceed $111.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. Available from: http://www.prweb.com/releases/cardiovascular-drugs/antihyperlipidemics/prweb3729014.htm
35. Geleijnse JM, Vermeer C, Grobbee DE, et al. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam study. J Nutr, 134, 3100-5.
36. Gundberg CM, Lian JB, Booth SL. (2012). Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr, 3, 149-157.
37. Haroon Y, Bacon DS, Sadowski JA. (1986). Liquid-chromatographic determination of vitamin K1 in plasma, with fluorometric detection. Clin Chem, 32, 1925-9.
38. Hirauchi K, Sakano T, Notsumoto S, et al. (1989a). Measurement of K vitamins in animal tissues by high-performance liquid chromatography with fluorimetric detection. J Chromatogr, 497, 131-7.
39. Hodges SJ, Bejui J, Leclercq M, Delmas PD. (1993). Detection and measurement of vitamins K1 and K2 in human cortical and trabecular bone. J Bone Miner Res, 8, 1005-8.
40. Howard LM, Payne AC. (2006). Health benefits of vitamin K2: a revolutionary natural treatment for heart disease and bone loss. Laguna Beach, CA: Basic Health Publications.
41. IARC. (2000). Monographs on the evaluation of carcinogenic risks to humans: vitamin K substances. World Health Organization publication, 76, 417-82.
42. Iwamoto J, Takeda T, Sato Y. (2006). Role of vitamin K2 in the treatment of postmenopausal osteoporosis. Curr Drug Saf, 1, 87-97.
43. Jie KG, Bots ML, Vermeer C, et al. (1996). Vitamin K status and bone mass in women with and without aortic atherosclerosis: a populationbased study. Calcif Tissue Int, 59, 352-6.
44. Kaneki M, Mizuno Y, Hosoi T, et al. (1995). Serum concentration of vitamin K in elderly women with involutional osteoporosis. Nihon Ronen Igakkai Zasshi, 32, 195-200.
45. Knapen MHJ, Drummen NE, Smit E, et al. (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int, 24, 2499-507.
46. Krishna C. (2005). Solid-state fermentation systems-an overview. Crit Rev Biotechnol, 25, 1-30.
47. Kuchma SL, O'Toole GA. (2000). Surface-induced and biofilm-induced changes in gene expression. Curr Opin Biotechnol, 11, 429-33.
48. Li J, Lin JC,Wang H, et al. (2003). Novel role of vitamin K in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci, 23, 5816-26.
49. Lloyd-Jones D, Adams RJ, Brown TM, et al. (2010). Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation, 121, 948-54.
50. Mahanama R, Berenjian A, Talbot A, et al. (2011a). Enhanced production of menaquinone 7 via solid substrate fermentation from Bacillus subtilis. Int J Food Eng, 7, Article 17.
51. Mahanama R, Berenjian A, Talbot A, et al. (2011b). Solid-substrate fermentation of menaquinone 7 with Bacillus subtilis: comparison of continuous rotation with stationary bed fermentation at different initial moisture levels. Proceedings of Chemeca; 2011; Sydney, NSW: Engineers Australia, 315-24.
52. Mahanama R, Berenjian A, Talbot A, et al. (2012a). Modeling Menaquinone 7 production in tray type solid state fermenter. ANZIAM J, 53, 354-72.
53. Mahanama R, Berenjian A, Dehghani F, Kavanagh J. (2012b). Modeling the effect of bed height and particle size for vitamin K2 production in a static bed fermenter. Eng Lett, 20, 16-9.
54. McFarlane SI, Muniyappa R, Shin JJ, et al. (2004). Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocr, 23, 1-10.
55. Meganathan R. (2001). Ubiquinone biosynthesis in microorganisms. FEMS Microbiol Lett, 61, 173-218.
56. Miki T, Nakatsuka K, Naka H, et al. (2003). Vitamin K 2 (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab, 21, 161-5.
57. Mitchell DA, Berovic M, Krieger N. (2000). Biochemical engineering aspects of solid state bioprocessing. Adv Biochem Eng Biotechnol, 68, 61-138.
58. Morishita T, Tamura N, Makino T, Kudo S. (1999). Production of menaquinone by lactic acid bacteria. J Dairy Sci, 82, 1897-903.
59. Nattopharma (2012). Annual Report. Available from: http://www.nattopharma.com/2012.html [last accessed 30 Aug 2013]
60. Orimo H, Nakamura T, Hosoi T, et al. (2012). Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos, 7, 3-20.
61. Ozuru R, Sugimoto T, Yamaguchi T, Chihara K. (2002). Time-dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. Endocr, 49, 363-70.
62. Pandey A. (1992). Recent process developments in solid-state fermentation. Process Biochem, 27, 109-17.
63. Piironen V, Koivu T, Tammisalo O, Mattila P. (1997). Determination of phylloquinone in oils, margarines and butter by high-performance liquid chromatography with electrochemical detection. Food Chem, 59, 473-80.
64. Quinlan PT. (2007). Unilever res vlaardingen. Vitamin k2 containing food product. European Patent 1153548.
65. Rajagopalan S, Modak J. (1995). Modeling of heat and mass transfer for solid state fermentation process in tray bioreactor. Bioprocess Biosyst Eng, 13, 161-9.
66. Sato T, Yamada Y, Ohtani Y, et al. (2001a). Efficient production of menaquinone (vitamin K2) by a menadione-resistant mutant of Bacillus subtilis. J Ind Microbiol Biotechnol, 26, 115-20.
67. Sato T, Yamada Y, Ohtani Y, et al. (2001b). Production of Menaquinone (vitamin K2)-7 by Bacillus subtilis. J Biosci Bioeng, 91, 16-20.
68. Schallmey M, Singh A, Ward OP. (2004). Developments in the use of Bacillus species for industrial production. Can J Microbiol, 50, 1-17.
69. Schurgers LJ, Teunissen KJ, Hamulyák K, et al. (2007). Vitamin Kcontaining dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood, 109, 3279-83.
70. Sennerby U, Melhus H, Gedeborg R, et al. (2009). Cardiovascular diseases and risk of hip fracture. JAMA, 302, 1666-73.
71. Seto H, Jinnai Y, Hiratsuka T, et al. (2008). Studies on a new biosynthetic pathway for menaquinone. J Am Chem Soc, 130, 5614-5.
72. Shahidi F. (2006). Nutraceutical and specialty lipids and their coproducts. Boca Raton, FL: CRC Press/Taylor Francis.
73. Shea MK, Holden RM. (2012). Vitamin K status and vascular calcification: evidence from observational and clinical studies. Adv Nutr, 3, 158-65.
74. Shearer MJ. (1992). Vitamin K metabolism and nutriture. Blood Rev, 6, 92-104.
75. Shearer MJ, Newman P. (2008). Metabolism and cell biology of vitamin K. J Thromb Haemost, 100, 530-47.
76. Shiraki M, Shiraki Y, Aoki C, Miura M. (2000). Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res, 15, 515-21.
77. Skattebol L, Aukrust IR. (2010). Process for the preparation of vitamin K2. European Patent 2346806 A1.
78. Sonenshein AL, Hoch JA, Losick R. (2002). Bacillus subtilis and its closest relatives. Washington, DC: ASM Press.
79. Sumi H. (2004). Edible compositions of Bacillus subtilis natto cells containing water-soluble vitamin K. US Patent 6677141.
80. Sumi H, Asano N, Yatagai C. (2005). Additional effect of some nutrients and biological-active substances by Bacillus natto treatment of raw wheat. J Brew Japan, 100, 449-53.
81. Survase S, Bajaj I, Singhai RS. (2006). Biotechnological production of vitamins. Food Technol Biotech, 44, 381-96.
82. Suttie JW. (1995). The importance of menaquinone in human nutrition. Annu Rev Nutr, 15, 399-417.
83. Suvarna K, Stevenson D, Meganathan R, Hudspeth ME. (1998). Menaquinone (vitamin K2) biosynthesis: localization and characterization of the menA gene from Escherichia coli. J Bacteriol, 180, 2782-7.
84. Takenaka T, Inoue S, Takenaka Y, et al. (2002). Effects of vitamin K2 (menaquinone-7) from fermented okara on ALPase activity of human dental pulp. Nippon Shokuhin Kagaku Kogaku Kaishi, 49, 348-52.
85. Tamatani M, Morimoto S, Nakajima M, et al. (1998). Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. Metabolism, 47, 195-9.
86. Tani Y, Asahi S, Yamada H. (1984). Vitamin K2 (menaquinone): screening of producing microorganisms and production by Flavobacterium meningosepticurn. J Ferment Technol, 62, 321-7.
87. Tani Y, Taguchi H. (1989). Extracellular production of menaquinone-4 by a mutant of Flavobacterium sp. 238-7 with a detergent-supplemented culture. J Biosci Bioeng, 67, 102-6.
88. Tankó LB, Christiansen C, Cox DA, et al. (2005). Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res, 20, 1912-20.
89. Truong JT, Booth SL. (2011). Emerging issues in vitamin K research. J Evid Based Complementary Altern Med, 16, 73-9.
90. Tsukamoto Y, Ichise H, Kakuda H, Yamaguchi M. (2000a). Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and g-carboxylated osteocalcin concentration in normal individuals. J Bone Miner Metab, 18, 216-22.
91. Tsukamoto Y, Ichise H, Yamaguchi M. (2000b). Prolonged intake of dietary fermented soybeans (Natto) with the reinforced vitamin K2 (menaquinone-7) enhances circulating gamma-carboxylated osteocalcin concentration in normal individuals. J Health Sci, 46, 317-21.
92. Tsukamoto Y, Kasai M, Kakuda H. (2001). Construction of a Bacillus subtilis (natto) with high productivity of vitamin K2 (menaquinone-7) by analog resistance. Biosci Biotechnol Biochem, 65, 2007-15.
93. Usui Y, Tanimura H, Nishimura N, et al. (1990). Vitamin K concentrations in the plasma and liver of surgical patients. Am J Clin Nutr, 51, 846-52.
94. Van Brunt J. (1988). Scale-up: how big is big enough? Biotechnol, 6, 480-5.
95. Vermeer C, Braam L. (2001). Role of K vitamins in the regulation of tissue calcification. J Bone Miner Metab, 19, 201-6.
96. Vermeer C. (2012). Vitamin K: the effect on health beyond coagulation-an overview. Food Nutr Res, 56, 166-173.
97. Weber FJ, Tramper J, Rinzema A. (1999). A simplified material and energy balance approach for process development and scale-up of Coniothyrium minitans conidia production by solid-state cultivation in a packed-bed reactor. Biotechnol Bioeng, 65, 447-58.
98. Weber FJ, Oostra J, Tramper J, Rinzema A. (2002). Validation of a model for process development and scale-up of packed-bed solid-state bioreactors. Biotechnol Bioeng, 77, 381-93.
99. WHO. (2011). Global atlas on cardiovascular disease prevention and control. Avaible at: http://www.who.int/cardiovascular-diseases/publications/atlas-cvd/en/index.html
100. Wu CH, Chou CC. (2009). Enhancement of aglycone, vitamin K2 and superoxide dismutase activity of black soybean through fermentation with Bacillus subtilis BCRC 14715 at different temperatures. J Agric Food Chem, 57, 10695-700.
101. Wu WJ. (2011). Food science/microbiology: isolation and identification of Bacillus amyloliquefaciens BY01 with high productivity of menaquinone for cheonggukjang production. J Korean Soc Appl Biol Chem, 54, 783-9.
102. Wu WJ, Ahn BY. (2011a). Improved menaquinone (Vitamin K 2) production in cheonggukjang by optimization of the fermentation conditions. Food Sci Biotechnol, 20, 1585-91.
103. Wu WJ, Ahn BY. (2011b). Isolation and identification of Bacillus amyloliquefaciens BY01 with high productivity of menaquinone for cheonggukjang production. J Korean Soc Appl Bi, 54, 783-9.
104. Yamaguchi M, Hideaki T, Gao YH, et al. (1999). Effect of vitamin K2 (menaquinone-7) in fermented soybean (natto) on bone loss in ovariectomized rats. J Bone Miner Metab, 17, 23-29.
105. Yang ST. (2007). Bioprocessing for value-added products from renewable resources: new technologies and applications. Dublin, OH: Elsevier Science Publication.
106. Zadražil F, Brunnert H. (1981). Investigation of physical parameters important for the solid state fermentation of straw by white rot fungi. Appl Microbiol Biotechnol, 11, 183-8.